Results about: cancer

Recent years have seen a paradigm shift in our understanding of gene activity and regulation. It is now clear that processing of primary transcripts as well as translational control open a myriad of opportunities for gene regulation, which are extensively used in virtually every human gene.

<p>Angel R Nebreda</p>

The Signalling and Cell Cycle Laboratory focuses on studying the basic mechanisms of cell regulation, especially regarding how external signals are interpreted by cells to modulate cell proliferation, differentiation and survival. Our research centers on two main subjects:


The recognition of many types of DNA lesions activates the cellular DNA damage response (DDR). The DDR orchestrates the appropriate cellular programs to maintain genome integrity after genotoxic stress.

A high resolution description of the structure and dynamics of proteins is a very useful tool to study the properties and the function of these important biomacromolecules and, most importantly, to understand how changes in sequence or environment can lead to disease.


Candidates with a strong interest in the microtubule cytoskeleton who would like to join our group should e-mail a cover letter with CV including contact information for references to

Our research focuses on three angles of peptide and protein chemistry: the design, synthesis and structure of bioactive molecules. From a structural perspective, we apply modern NMR techniques to study complex molecular recognition processes.

La Marató premia sis projectes amb participació de l'IRB Barcelona

La fundació finançarà 43 projectes de recerca en càncer

Desenvolupen un algoritme basat en machine learning per predir quins pacients de càncer poden beneficiar-se de la immunoteràpia

Mitjançant l’ús de machine learning, els investigadors han creat una eina que detecta les mutacions genètiques que activen el sistema immunitari, la qual cosa contribueix a identificar quins pacients amb càncer tenen més probabilitats de beneficiar-se de la immunoteràpia.

L'algoritme també revela quines persones amb determinades malalties hereditàries podrien beneficiar-se d'un tipus de medicaments ja existents.

El potencial de la nova tecnologia es descriu avui a Nature Genetics per part d’investigadors de l'IRB Barcelona, el Centre de Regulació Genòmica i la Universitat de Radboud